Talazoparib tosylate (Synonyms: 他拉唑帕利甲苯磺酸盐; BMN 673ts)
目录号: PL08919 纯度: ≥99%
CAS No. :1373431-65-2
商品编号 规格 价格 会员价 是否有货 数量
PL08919-2mg 2mg ¥1655.00 请登录
PL08919-5mg 5mg ¥2491.00 请登录
PL08919-10mg 10mg ¥3937.00 请登录
PL08919-50mg 50mg ¥10447.00 请登录
PL08919-100mg 100mg ¥17680.00 请登录
PL08919-200mg 200mg ¥27323.00 请登录
PL08919-500mg 500mg 询价 询价
PL08919-1g 1g 询价 询价
PL08919-10mM*1mLinDMSO 10mM*1mLinDMSO ¥3028.00 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
Talazoparib tosylate
英文名称
Talazoparib tosylate
英文别名
TALAZOPARIB TOSYLATE;BMN 673TS;02WK9U5NZC;Talazoparib tosylate [USAN];Talazoparib tosylate (USAN);Talzenna (TN);Talazoparib tosilate (JAN);(8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido(4,3,2-de)phthalazin-3-one MONO(4-methylbenzenesulfonate);3H-Pyrido(4,3,2-de)phthalazin-3-one, 5-fluoro-8-(4-fluorophenyl)-2,7,8,9-tetrahydro-9-(1-methyl-1H-1;1373431-65-2 (tosylate);BMN 673ts;Talazoparib tosylate
Cas No.
1373431-65-2
分子式
C26H22F2N6O4S
分子量
552.55
包装储存
4°C, sealed storage, away from moistur In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
产品详情
Talazoparib tosylate (BMN 673ts) 是一种新型,高效,有可口服活性的 PARP1/2 抑制剂,抑制PARP1的IC50 值为 0.57 nM。
生物活性
Talazoparib tosylate (BMN 673ts) is a novel, potent and orally available PARP1/2 inhibitor with an IC 50 of 0.57 nM for PARP1.
性状
Solid
IC50 & Target[1][2]
IC50: 0.57 nM (PARP1)
体外研究(In Vitro)
Talazoparib is a potent PARP1/2 inhibitor (PARP1 IC50=0.57 nM), it has no effect on PARG activity at concentrations up to 1 μM. Talazoparib binds to PARP1 with a dissociation constant (KD) of 0.29 nM. Talazoparib inhibits PARP1 and -2 to a similar extent, with Kis of 1.20 and 0.85 nM, respectively. Talazoparib selectively targets tumor cells with BRCA1, BRCA2, or PTEN gene defects with 20- to more than 200-fold greater potency than existing PARP1/2 inhibitors. Talazoparib targets tumor cells with homologous recombination gene defects. Tumor models that are either BRCA1-deficient (MX-1 and SUM149) or BRCA2-deficient (Capan-1) are profoundly sensitive to Talazoparib. Talazoparib induces nuclear γ-H2AX foci at concentrations as low as 100 pM. has not independently confirmed the accuracy of
体内研究(In Vivo)
Talazoparib is readily orally bioavailable, with more than 40% absolute oral bioavailability in rats when dosed in carboxylmethyl cellulose. Oral administration of Talazoparib elicits remarkable antitumor activity; xenografted tumors that carry defects in DNA repair due to BRCA mutations or PTEN deficiency are profoundly sensitive to oral Talazoparib treatment at well-tolerated doses in mice. Synergistic or additive antitumor effects are also found when Talazoparib is combined with temozolomide, SN38, or platinum drugs. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
4°C, sealed storage, away from moistur In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
ClinicalTrial
参考文献
[1]. Shen Y, et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res. 2013 Sep 15;19(18):5003-15.
溶解度数据
In Vitro: DMSO : ≥ 108 mg/mL (195.46 mM)配制储备液
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2